GSK Inks “Transformational” Licensing Agreement With Onco Therapies To Extend Reach In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - British drug maker GlaxoSmithKline has announced a comprehensive product licensing deal, in what it calls a "transformational agreement" with Onco Therapies - a joint venture between South Africa's largest drug firm Aspen Pharmacare and one of India's largest generic drug exporters Strides Arcolab
You may also be interested in...
After Pfizer And GSK, India’s Agila Teams Up With Lilly For Oncology Drugs In Emerging Markets
Over the last year, Agila has gone ballistic with its filings and approvals for anti-cancer injectables in the U.S., and after inking a deal with Lilly, it is likely to reach a new high.
Pfizer Delves Deeper In Generics Partnership With Strides Arcolab
Pfizer's supply agreement with India-based Strides Arcolab now covers 45 products with a more expansive global marketing reach.
Pfizer Delves Deeper In Generics Partnership With Strides Arcolab
Pfizer's supply agreement with India-based Strides Arcolab now covers 45 products with a more expansive global marketing reach.